Clinical trials: Large Bowel Cancer
BRAF V600E, Metastatic Colorectal Cancer
A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
Encorafenib is currently being developed (with or without binimetinib), in combination with cetuximab, for the treatment of adult patients with B-RAF proto-oncogene, serine/threonine kinase V600E mutant (BRAF V600E) metastatic…
- Trial name
- NAUTICALCRC (NCT05004350)
- Testing
- Encorafenib, Cetuximab, FOLFIRI
- Where
- 34 sites in China
- Volunteers
- 107 people
- Sponsor
- Pierre Fabre Medicament
Metastatic Carcinoma in the Liver, Recurrent Colorectal Carcinoma
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver
This early phase IIA trial studies how well celecoxib, recombinant interferon alfa-2b, and rintatolimod work in treating patients with colorectal cancer that as spread to the liver.
- Conditions
- Metastatic Carcinoma in the Liver, Recurrent Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7
- Trial name
- NCT03403634
- Testing
- Celecoxib, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Roswell Park Cancer Institute
Precancerous Condition
Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
This randomized phase III trial is studying eflornithine and sulindac to see how well they work compared to a placebo in preventing colorectal cancer in patients with colon polyps.
- Trial name
- NCT00118365
- Testing
- eflornithine, sulindac, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 375 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Colon Cancer
Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy
Background: Drugs given to treat cancer (chemotherapy) can weaken the human immune system. But it can also become weaker because of aging.
- Conditions
- Breast Cancer, Colon Cancer, Bladder Cancer
- Trial name
- NCT01339000
- Testing
- Glycosylated Recombinant Human Interleukin-7, Diphtheria/Tetanus Vaccine, Polio Vaccine
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of RMC-4630 and cobimetinib in adult participants with relapsed/refractory solid tumors with specific…
- Trial name
- NCT03989115
- Testing
- RMC-4630, Cobimetinib, Drug: Osimertinib
- Where
- 24 sites in United States, South Korea
- Volunteers
- 113 people
- Sponsor
- Revolution Medicines, Inc.
Acute Myelogenous Leukemia, Ovarian Cancer
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer
- Trial name
- NCT03761914
- Testing
- galinpepimut-S, pembrolizumab, Montanide
- Where
- 12 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sellas Life Sciences Group
Esophageal Neoplasms, Lung Neoplasms
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
Background: Mithramycin is a new cancer drug. In another study, people with chest cancer took the drug 6 hours a day for 7 straight days. Many of them had liver damage as a side effect.
- Conditions
- Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymus Neoplasms
- Trial name
- NCT02859415
- Testing
- Mithramycin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Neoplasms
Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
The objective of this Phase III study is to evaluate the efficacy of nintedanib in patients with metastatic colorectal cancer (mCRC) after failure of previous treatment with standard chemotherapy and biological agents.
- Trial name
- NCT02149108
- Testing
- Nintedanib (BIBF 1120), BSC
- Where
- 129 sites in United States, Argentina and 23 more
- Volunteers
- 768 people
- Sponsor
- Boehringer Ingelheim
Colorectal Cancer
Risk Stratification to Promote Effective Shared Decision-Making for Colorectal Cancer Screening
Shared decision-making (SDM) has been advocated as a strategy for increasing colorectal cancer (CRC) screening rates. Our studies to date suggest that while the use of a novel computer-based decision aid facilitates several…
- Trial name
- NCT01596582
- Testing
- Risk Assessment
- Where
- United States
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Boston Medical Center
Colorectal Cancer
Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy
To assess the safety and efficacy of weekly (70 mg per week) and daily (10 mg per day) everolimus in patients with metastatic colorectal cancer whose cancer has progressed despite prior treatment with targeted therapy and…
- Trial name
- NCT00419159
- Testing
- Everolimus (RAD001)
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Neoplasms Malignant
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
This is an open-label, two-part study to evaluate the safety and tolerability of combination treatment with dalotuzumab + MK-2206, dalotuzumab + MK-0752, or dalotuzumab + ridaforolimus (MK-8669).
- Trial name
- NCT01243762
- Testing
- dalotuzumab, MK-0752, ridaforolimus
- Volunteers
- 47 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Colorectal Cancer
Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer
The purpose of the study is to evaluate the safety and efficacy of FOLFIRI (Irinotecan, Leucovorin and 5 Fluorouracil) chemotherapy when combined with sunitinib or FOLFIRI chemotherapy without adding sunitinib as the first line…
- Trial name
- NCT00457691
- Testing
- 5 fluorouracil, irinotecan, levo- leucovorin
- Where
- 132 sites in Argentina, Australia and 32 more
- Volunteers
- 768 people
- Sponsor
- Pfizer
Advanced Colorectal Carcinoma
A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions
A Phase 1 dose escalation study to evaluate APR003 in patients with advanced colorectal cancer (CRC) with malignant liver lesions
- Trial name
- NCT04645797
- Testing
- APR003
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Apros Therapeutics, Inc
Ulcerative Colitis
Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission
This randomized, pilot phase I trial studies the side effects of berberine chloride in treating patients with ulcerative colitis and who are in remission (a decrease in or disappearance of signs and symptoms of cancer) to reduce…
- Trial name
- NCT02365480
- Testing
- Berberine Chloride, Laboratory Biomarker Analysis
- Where
- 2 sites in United States, China
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Colonoscopic Skill Acquisition and Transfer Via Simulated Curriculum of Progressive Training
It is hypothesized that a progressive simulated learning strategy will result in better global clinical performance (e.g., technical, communication) and transfer of endoscopic skill, as compared with a high-fidelity simulation…
- Trial name
- NCT02000180
- Testing
- Progressive Group
- Where
- Canada
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Adenomatous Polyps
Does Cap Assisted Colonoscopy Improve Detection of Adenomatous Polyps? (CAP Trial)
Effectiveness of screening colonoscopy in cancer prevention relies on the detection and removal of adenomatous polyps. However, a substantial rate of adenomas is missed during a colonoscopy.
- Trial name
- CAP (NCT01935180)
- Testing
- Colonoscopy Cap
- Where
- 2 sites in United States
- Volunteers
- 1,148 people, healthy volunteers welcome
- Sponsor
- White River Junction Veterans Affairs Medical Center
Breast Cancer, Prostate Cancer
Survivorship Promotion In Reducing IGF-1 Trial
This is a prospective, single-center randomized trial with three arms, and an allocation ratio of 1:1:1. The study design is an efficacy study to evaluate the effect of metformin and coach-directed behavioral weight loss versus…
- Conditions
- Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer
- Trial name
- SPIRIT (NCT02431676)
- Testing
- Metformin, Coach Directed Behavioral Weight Loss, Self-control weight loss
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lung Cancer, Breast Cancer
Measuring and Improving the Safety of Test Result Follow-Up
Improving communication is foundational to improving patient safety. Electronic health records (EHRs) can improve communication, but also introduce unique vulnerabilities.
- Conditions
- Lung Cancer, Breast Cancer, Colon Cancer, Bladder Cancer
- Trial name
- NCT04166240
- Testing
- SAFER TRACKS Intervention
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- VA Office of Research and Development
Carcinoma of the Appendix, Colorectal Cancer
Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer
RATIONALE: Thalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Giving thalidomide after surgery and chemotherapy may kill any remaining tumor cells.
- Trial name
- NCT00310076
- Testing
- thalidomide, surgery
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Wake Forest University Health Sciences
Colorectal Cancer, High Cholesterol
Online Trial Examining Validity of the Shared Decision Making Process Survey With Video Vignettes
This study will recruit subjects online and randomly assigned them to one of four arms. The arms vary by clinical decision (colorectal cancer screening or treatment of high cholesterol) by video order (poor shared decision making…
- Trial name
- NCT04317274
- Testing
- Good high cholesterol video, Poor high cholesterol video, Good colon cancer screening video
- Where
- United States
- Volunteers
- 401 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital